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 During diet-induced dysbiosis the gut vascular barrier is
disrupted.
 Gut vascular barrier disruption is responsible for the translo-
cation of bacteria or bacterial products systemically.
 Inhibiting gut vascular barrier disruption prevents the
development of non-alcoholic steatohepatitis.
 Obeticholic acid can control gut vascular barrier disruption
both in a preventive and therapeutic way.Juliette Mouries, Paola Brescia, Alessandra
Silvestri, ..., Luciano Adorini, Giuseppe
Penna, Maria Rescigno
Correspondence
maria.rescigno@hunimed.eu
(M. Rescigno)
Lay summary
The incidence of fatty liver disease is
reaching epidemic levels in the USA, with
more than 30% of adults having NAFLD
(non-alcoholic fatty liver disease), which
can progress to more severe non-alcoholic
steatohepatitis (NASH). Herein, we show
that disruption of the intestinal epithelial
barrier and gut vascular barrier are early
events in the development of NASH. We
show that the drug obeticholic acid pro-
tects against barrier disruption and there-
by prevents the development of NASH,
providing further evidence for its use in
the prevention or treatment of NASH.Genetic and Metabolic Diseases. This is an open access article under the CC BY-NC-ND
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Background & Aims: Fatty liver disease, including non-
alcoholic fatty liver (NAFLD) and steatohepatitis (NASH), has
been associated with increased intestinal barrier permeability
and translocation of bacteria or bacterial products into the
blood circulation. In this study, we aimed to unravel the role
of both intestinal barrier integrity and microbiota in NAFLD/
NASH development.
Methods: C57BL/6J mice were fed with high-fat diet (HFD) or
methionine-choline-deficient diet for 1 week or longer to reca-
pitulate aspects of NASH (steatosis, inflammation, insulin resis-
tance). Genetic and pharmacological strategies were then used
to modulate intestinal barrier integrity.
Results:We show that disruption of the intestinal epithelial
barrier and gut vascular barrier (GVB) are early events in NASH
pathogenesis. Mice fed HFD for only 1 week undergo a
diet-induced dysbiosis that drives GVB damage and bacterial
translocation into the liver. Fecal microbiota transplantation
from HFD-fed mice into specific pathogen-free recipients
induces GVB damage and epididymal adipose tissue
enlargement. GVB disruption depends on interference with
the WNT/b-catenin signaling pathway, as shown by genetic
intervention driving b-catenin activation only in endothelial
cells, preventing GVB disruption and NASH development. The
bile acid analogue and farnesoid X receptor agonist obeticholic
acid (OCA) drives b-catenin activation in endothelial cells.
Accordingly, pharmacologic intervention with OCA protects
against GVB disruption, both as a preventive and therapeutic
agent. Importantly, we found upregulation of the GVB leakage
marker in the colon of patients with NASH.
Conclusions:We have identified a new player in NASH devel-
opment, the GVB, whose damage leads to bacteria or bacterial
product translocation into the blood circulation. Treatment
Keywords: Non-alcoholic fatty liver disease; miRNA; Expression profile; Diagnostic
accuracy.
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aimed at restoring b-catenin activation in endothelial cells, such
as administration of OCA, protects against GVB damage and
NASH development.
Lay summary: The incidence of fatty liver disease is reaching
epidemic levels in the USA, with more than 30% of adults having
NAFLD (non-alcoholic fatty liver disease), which can progress to
more severe non-alcoholic steatohepatitis (NASH). Herein, we
show that disruption of the intestinal epithelial barrier and
gut vascular barrier are early events in the development of
NASH. We show that the drug obeticholic acid protects against
barrier disruption and thereby prevents the development of
NASH, providing further evidence for its use in the prevention
or treatment of NASH.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Fatty liver disease is characterized by a series of pathological
conditions ranging from hepatic lipid accumulation (steatosis),
to hepatocyte degeneration (ballooning), inflammation (steato-
hepatitis) and, eventually, cirrhosis and hepatocellular carci-
noma.1,2 Fatty liver disease may be the result of long-term
excessive ethanol consumption (alcoholic liver disease) or of
visceral obesity and metabolic syndrome without ethanol con-
sumption, leading to non-alcoholic fatty liver disease (NAFLD)
which can evolve to non-alcoholic steatohepatitis (NASH).3
Several factors, likely acting in parallel, contribute to NASH
development, including genetic predisposition, epigenetic
changes, insulin resistance, abnormal lipid metabolism, oxida-
tive stress, lipotoxicity, mitochondrial dysfunction, endoplasmic
reticulum stress, hepatocyte apoptosis, activation of hepatic
stellate cells, activation and recruitment of immune cells with
production of inflammatory cytokines, altered adipokines, and
gut dysbiosis.4,5
The important role of the gut microbiota has been clearly
established both in preclinical NAFLD/NASH models and in
patients with NASH.6,7 Bacterial overgrowth in the small intes-
tine, as well as qualitative microbiome abnormalities can impair019 vol. 71 j 1216–1228
the barrier functions of the intestinal mucosa, leading to
enhanced mucosa permeability and subsequent translocation
of endotoxin to the bloodstream.8 Patients with NASH present
increased intestinal permeability and small intestinal bacterial
overgrowth, which correlate with the severity of steatosis.9 Sim-
ilarly, mice deficient in Jam-A, an integral component of tight
junctions, which control the paracellular route of solutes and
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ing the epithelium,10 are also more susceptible to NASH devel-
opment.11 Together, these data suggest that increased gut
permeability represents an important mechanism in NASH
pathogenesis, leading to the accumulation of endotoxin and
bacterial components in the liver, and subsequently to the
induction of inflammatory responses, through activation of pat-
tern recognition receptors.
The intestinal epithelial barrier (IEB) is composed of several
elements, which are more or less accessible to bacteria and their
derivatives. The first line of defense is provided by the mucus
layer, thicker in the ileum, cecum and colon where microbes
mainly reside.12 The mucus physically separates the microbiota
from the second physical barrier composed of epithelial cells,
sealed by tight junctions.10 We have described that just below
the epithelium an additional cellular barrier, the gut vascular
barrier (GVB), controls entry into the portal circulation and
access to the liver.13,14 Thus, if a molecule or a microorganism
crosses the epithelial barrier, it will remain in the lamina propria,
unless the GVB is also impaired. Indeed, for bacteria to reach the
systemic circulation the GVB must be disrupted. Enteric patho-
gens such as Salmonella typhimurium, have established strategies
to elude the GVB by interfering with the WNT/b-catenin signal-
ing pathway.14 In addition, the GVB is also disrupted in some
pathological conditions such as in celiac disease (in patients with
high serum levels of liver aminotransferases),13 and in patients
with ankylosing spondylitis.15 In the context of NASH, it is
unclear if increased intestinal permeability due to disrupted
IEB alone is sufficient to induce bacteria and LPS translocation
and drive liver damage, or if GVB disruption is also required.
Obeticholic acid (OCA), a derivative of the bile acid chen-
odeoxycholic acid and a potent agonist of the farnesoid X recep-
tor (FXR)16 has been shown to play a role in controlling
intestinal permeability,17 gut barrier dysfunction and bacterial
translocation.18 OCA ameliorates disease in patients with type
II diabetes mellitus and NAFLD,19 and in patients with NASH.20
However, the precise roles of bile acids and FXR in controlling
IEB or GVB permeability are still unknown.
Here, we show that patients with NASH display increased
intestinal expression of a marker of GVB leakage. This was par-
alleled by mouse studies showing that one of the earliest events
in experimental NASH development is disruption of both the IEB
and GVB, which are dependent on dysbiosis induced by HFD.
After HFD feeding, the initial event observed at 48 h is IEB dis-
ruption followed by GVB damage at 1 week. Both genetic
manipulation of the WNT/b-catenin signaling pathway,
involved in GVB integrity, and pharmacological treatment with
OCA, prevent GVB disruption in mice and protect against NASH
development.
Materials and methods
Mice and diets
C57BL/6J mice were purchased from Charles River Laboratories
(Calco, Italy). Cdh5(PAC)-CreERT2 mice were used and
Journal of Hepatology 20maintained as previously reported.13 These mice were crossed
to b-cateninlox(ex3)/lox(ex3), containing flox sequences flanking
exon 3 of b-catenin (Ctnnb1).49 To induce Cre recombination,
mice were fed with tamoxifen-enriched diet (TAM 400) for
2 days and then kept at least 5 days on chow diet (4RF21) to
reduce the direct side effects of tamoxifen on the liver. Mice
were maintained on chow diet or 10% fat isocaloric
(TD.06416) as control diets, 45% lard high-fat diet (HFD,
TD.06415), 60% lard HFD (TD.06414), or methionine-choline-
deficient diet (MCDD, TD.90262). All diets were purchased from
Harlan Laboratories. In some experiments, 30 mg/kg OCA
(Intercept Pharmaceuticals, New York) was administered daily
via oral gavage or feeding with OCA-supplemented diets.
In all experiments, age- and gender-matched mice were
used. All mice were maintained on a 12 h light-dark cycle.
Experiments were performed in accordance with the guidelines
established in the Principles of Laboratory Animal Care (direc-
tive 86/609/EEC) and approved by the Italian Ministry of Health.
Mice were not randomized. Investigators were not blinded dur-
ing experimental mice allocation and outcome assessment.
Analysis of serum parameters
Serum alanine aminotransferase (ALT) activity was measured
using a kit (MAK052, Sigma-Aldrich, St. Louis, MO) and LPS
was measured by the Limulus Amebocyte Lysate assay (Pierce),
both according to the manufacturer’s instructions.
Immunofluorescence
Intestinal and liver samples were fixed overnight in
paraformaldehyde, L-Lysine pH 7.4 and NaIO4 (PLP buffer). They
were then dehydrated in 20% sucrose for at least 4 h and
included in OCT compound (Sakura). Alternatively, whole pieces
of tissue, were stained directly after fixation in PLP to image
whole mount. 10 lm cryosections were rehydrated, blocked
with 0.1 M Tris-HCl pH 7.4, 2% FBS, 0.3% Triton X-100 and
stained with antibodies recognizing the following proteins:
PV1 (clone MECA32, BD Pharmingen, 1:100), ZO-1 (clone
ZO1-1A12, Invitrogen, 1:100), CD34 (clone RAM34, eBioscience,
1:50).
Tissues were then incubated with the appropriate
fluorophore-conjugated secondary antibody. Before imaging,
nuclei were counterstained with 40,6-diamidin -2-fenilindolo
(DAPI). Confocal microscopy was performed on a Leica SP8,
using oil immersion objectives with x40 or x63 magnification.
Fiji (ImageJ) software package was used for image analysis
and fluorescence quantification.
Flow cytometry on intestinal and liver samples
Liver, ileum or cecum samples were flushed and rinsed in cold
PBS, then moved to collagenase D (1 mg.ml1) at 37 C for
20 min. The reaction was stopped by adding cold EDTA contain-
ing FACS buffer (PBS, 10% FBS, 0.1% NaO3, 5 mM EDTA). Intesti-
nal tissues were crushed and resuspended for FACS staining
with the following antibodies: EpCAM, CD31, lyve-1, CD34,
ZO-1 for 20 min in the dark. Liver tissues were stained with
the following antibodies: CD45, CD3, CD4, CD8, Ly6C, Ly6G,
F4/80, CD11b. Cells were acquired on a CANTO II and data were
analyzed using FlowJo software.
Fluorescence in situ hybridization
For fluorescence in situ hybridization (FISH), 6 lm cryosections
were rehydrated with 4% PFA and incubated with 10 mg/ml1
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48 h in aerobic conditions at 37 C. Colony Forming Units (CFUs)
were counted after 24 h incubation, and CFUs per mg of tissue
Research Article Genetic and Metabolic Diseaseslysozyme (Sigma) in Tris-HCl 0.1 M (pH 7.4) for 30 min. Slices
were then washed and incubated with 5 ng.ml1 of probes
(mixed Eub338 and non-Eub in hybridization buffer (0.9 M
Table 1. Fluorescence in situ hybridization probes.
Gene Fluorochrome Sequence
Eub338 I FITC 50-GCT GCC TCC CGT AGG AGT-30
Eub338 II FITC 50-GCA GCC ACC CGT AGG TGT-30
Eub338 III FITC 50-GCT GCC ACC CGT AGG TGT-30
non-Eub Alexa 647 50-ACT CCT ACG GGA GGC AGC-30NaCl, 0.1% SDS) for 90 min at 58 C in a humid chamber. A
mix of probes were used, as shown in Table 1.
Samples were washed with Tris-HCl 0.1 M (pH 7.4) and
blocked with Tris-HCl 0.1 M pH 7.4 (2% FBS, 0.3% Triton X) for
30 min at room temperature. Then, they were stained with
anti-mouse CD45 (Clone 30-F11) for 1 h, washed and incubated
with the appropriate fluorophore-conjugated secondary anti-
body for 1 h. Before imaging, samples were counterstained with
DAPI. For each mouse, 4 to 8 images were taken, and the total
number of bacteria was determined. The frequency of bacteria
inside or outside CD45+ cells was then calculated.
Endothelial leakage analysis from in vivo endomicroscopy
Cellvizio Viewer software (Mauna Kea Technologies) was used
to extract the photograms from the endomicroscopy video. Only
photograms with vessels in focus and normal blood flow were
selected. At least 1 picture per time point was selected and 7
measurements were taken per picture. Measurements were
made using Image J as follows: straight lines perpendicular to
the vessel were drawn in each vessel within the picture and
grey value measured in each pixel along the line. Mean grey
value (MGV) of the vessel was calculated and background fluo-
rescence was subtracted. MGV of the immediate extravascular
space was calculated in the same way. To avoid bias in our mea-
surements, the same number of pixels were analyzed from the
intra and extravascular space in all measurements. We also
avoided measuring extravascular spaces where more than 1
vessel could contribute to the fluorescence values. Results are
shown as a ratio between mean extravascular fluorescence
and mean intravascular fluorescence. When extravasation was
too high to distinguish vessels from lamina propria a value of
1 was arbitrarily assigned.
Assessment of bacterial translocation
Intestinal pieces were aseptically collected, content was emp-
tied, and samples were weighted. They were washed for 10 s
in sterile PBS, then transferred into sterile PBS with 5% FBS with
0.5 mg/ml1 gentamycin. Intestinal samples were incubated for
Table 2. Demographic characteristics patients with NASH.
Patient Sex Age Steatosis Lobular in
1 M 50 1 1
2 M 62 3 1
3 M 77 n.d. n.d.
4 M 72 3 2
5 F 62 1 2
6 M 70 1 2
7 F 75 n.d. n.d.
8 M 52 2 1
9 M 35 3 1
NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; n.d., not determined.
1218 Journal of Hepatology 2030 min in gentamycin at 37 C, then rinsed in PBS before tissue
lysis with 0.5% sodium-deoxycholate. Lysed tissues were plated
on Sheep Blood Columbia Agar plates (BD) and incubated forwere determined.
Gut microbiota transplantation
Two groups of donor mice (5 per group) were fed Ctrl diet or
HFD for 1 week. After 7 days, 1 group was sacrificed, cecal and
colon content was harvested, pooled and gavaged into recipient
mice (5 per group). The next days, feces were harvested from
the second donor groups and gavaged into recipient mice
(0.05 mg/mouse), for 2 consecutive days. One week after the
first gavage, the intestines from recipient mice were harvested
in PLP.
Human specimens
Endoscopic specimens were collected from the colons of 9
patients with NASH (Table 2) and 5 healthy controls. Patients
were categorized as having NASH by evaluating the presence
of steatosis, lobular inflammation, and hepatocellular balloon-
ing on liver biopsies. These analyses were scored according to
the Pathology Committee of the NASH Clinical Research
Network.50
All tissues were obtained from patients, after signing an
informed consent, and handled anonymously. Comitato Etico
ASST Monza approved the study protocol.
Immunohistochemistry and tissue staining
PV1 immunohistochemistry was performed on 4 mm formalin-
fixed paraffin embedded human intestinal tissue sections. Fol-
lowing deparaffinization and re-hydration steps, the antigen is
retrieved with 1 mM EDTA (pH 8) at 95 C for 50 min and
endogenous peroxidases were quenched with 3% H2O2.
Slides were blocked (TBS 1x, BSA 2%, serum 2%, Tween20
0.02%) for 20 minutes at room temperature. Polyclonal antibody
against human PV1 protein (Sigma-Aldrich, 1:200) was used for
staining colon biopsies. Secondary anti-rabbit horseradish per-
oxidase antibody (DAKO, K4003) was used and signal was
detected using 3,30diaminobenzidine.
Sirius red (Sigma) was performed on 4 mm formalin-fixed
paraffin embedded mouse liver tissue sections according to
manufacturer protocol. Oil Red O (ORO) (Sigma) was performed
on PLP buffer fixed OCT embedded frozen liver sections accord-
ing to manufacturer’s protocol.
Bright field images were acquired with virtual slide
microscope VS120 (Olympus) using dry objective with x20
flammation Hepatocellular ballooning Total NAS score
0 2
1 5
n.d. n.d.
1 6
0 3
0 3
n.d. n.d.
0 3
0 4
19 vol. 71 j 1216–1228
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used for image analysis.
Statistical analysis
From 3 to 5 mice per group were included in all experiments to
ensure statistical significance, as the model is reproducible, and
the mouse population is homogenous.Statistical significance was determined with an unpaired
2-tailed t test, 1-way or 2-way ANOVA test, as indicated in the
figure legend. Error bars indicate SEM on all graphs. Prism 5.0
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Results
Intestinal epithelial and vascular barrier disruption are early
events in high-fat dietary regimen
HFD is a dietary regimen rich in animal saturated fat (45% lard),
known to induce a metabolic disorder leading to insulin
G
Ctrl diet HFD
Caecum
E
Epithelial
cells
Endothelial
cells
Colon
*** * **
* ** * **
0 100 200 300 0 100 200 300
Distance (μm) Distance (μm)
Whole mount caecum
Ctrl diet HFD
Ctrl HFD
15,000
10,000
5,000
0
ZO
-1
 M
FI
Ile
um
Ca
ec
um
Ile
um
Ca
ec
um
FD Ctrl diet HFD
PV
1 
M
FI
Du
od
en
um
Je
jun
um
Ile
um
Ca
ec
um
Co
lon
120
80
40
0
Ctrl HFD
ascular barrier. (A–C) Mice were fed with control (Ctrl) diet or HFD for 48 h
ined for CD34 (green), PV1 (red), ZO-1 (gradient), and DAPI (cyan) expression.
with a gradient (as indicated in the legend), and a dotted line indicating where
plays the intensity profiles of each marker. CFUs in ileum and cecum were
tine from mice fed for 1 week was imaged as (D) whole mount or (F) sections.
xpression. (G) Quantification of PV1 was performed on CD34+ area. Scale bar
ming units; HFD, high-fat diet; MFI, mean fluorescence intensity.
19 vol. 71 j 1216–1228 1219
Research Article Genetic and Metabolic Diseasesresistance, type II diabetes and NASH in C57BL/6 mice.21 We
first assessed whether HFD, compared to an isocaloric diet reg-
imen where calories are provided primarily by starch, could
alter the IEB and GVB. As a sign of epithelial damage, we ana-
lyzed the expression of tight junction protein ZO-1 and bacterial
translocation in the ileum and cecum lamina propria of HFD
versus control diet-fed C57BL/6 male mice at an early time point
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reduced expression of the tight junction protein ZO-1 on epithe-
lial cells (Fig. 1A,B). The mean fluorescence intensity of intesti-
nal epithelial cell-associated ZO-1 (blue line) was much lower in
the HFD than in control fed mice (Fig. 1A,B, profile plots, last
row). This correlated with increased bacterial translocation to
the ileum and cecum lamina propria (Fig. 1C). A reliable marker
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associated protein 1 (PV1), an integral membrane protein
associated to the diaphragms of endothelial fenestrae, by the
antibody MECA-32.13,14 We found that at 48 h there was no
increased exposure of PV1 in any of the conditions tested
(Fig. 1A,B, red line, profile plots, last row). However, at 1 week
after initiation of HFD, ZO-1 was downregulated in both epithe-
lial (EpCAM+) and CD34+ blood endothelial cells, as assessed by
confocal (Fig. 1D) and FACS (Fig. 1E) analysis in the cecum and
ileum. Also, in the colon we observed a reduction of ZO-1
expression in both endothelial and epithelial cells, although
not reaching a statistically significant difference compared to
control mice (data not shown). The expression of other tight
junction proteins such as Occludin, Claudin-3 and Claudin-5
was not altered by HFD feeding (Fig. S1). At the same time,
PV1 was significantly upregulated in the ileum and cecum of
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Journal of Hepatology 20HFD-fed mice (Fig. 1F,G). A similar scenario was observed in
the jejunum and colon (Fig. 1F,G).
These results suggest a sequential series of events following
HFD treatment: first the disruption of the IEB which allows
translocation of bacteria, or their molecular determinants, from
the lumen and subsequent impairment of the GVB. We thus
analyzed whether a high oral load of pathogen-associated
molecular patterns may mimic the observed effect. Injection
of LPS via oral gavage to mice induced a dramatic reduction of
ZO-1 expression at 24 h, indicating IEB damage; at 48 h LPS
induced a subsequent increase of PV1 expression in the
endothelium, which was dose-dependent, indicating GVB dis-
ruption when the endothelium is exposed to high concentra-
tions of LPS (Fig. S2).
We then analyzed whether at later times during HFD
feeding, when insulin resistance is established, the GVB is
LIVER: HFD B
E F
rl diet microbiota
→ recipient
HFD microbiota
→ recipient
J
**
Ctrl HFD
0
5
10
15
20
25
****
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 
R
at
io
 o
ut
si
de
:in
si
de
AU
C
 R
at
io
 M
FI
 
ou
ts
id
e:
in
si
de
Ctrl HFD
100
75
50
0
25F
re
qu
en
cy
Ctrl HFD
Inside CD45
Outside CD45
0
0.8
1.0
0.6
0.4
0.2
0 20 3010
*200
150
100
50
0
Ctrl HFD
PV
1 
M
FI
Time (min)
Mice were fed with control (Ctrl) diet or HFD for 1 week, and (A) liver sections
e) and DAPI (blue) staining. Side images show merged and individual staining
es 10 lm. (B) Bacteria were enumerated for each mouse, and percentage of
sured in the serum of 1-week HFD-fed mice. (D–F) One-week-fed mice were
focal microscopy. Representative photograms from the endomicroscopy video
of the fluorescence was measured as described in materials and methods. (E)
each individual mouse. Fecal microbiota transplant of 1-week-fed donors was
ods. Recipients were analyzed 1 week later. (H) Organ and body weight were
ed for PV1 (red), CD34 (green) and DAPI (blue), scale bar indicates 50 lm.
*p <0.0005; ****p <0.0001 unpaired 2-tailed t test. AUC, area under the curve;
gut vascular barrier; HFD, high-fat diet; LPS, lipopolysaccharide; MFI, mean
19 vol. 71 j 1216–1228 1221
Research Article Genetic and Metabolic Diseasescompromised, and whether this correlates with an increased
inflammatory response within the liver. To this aim, mice were
fed a diet containing 60% fat (60% HFD) which, unlike 45% HFD,
induced an inflammatory response in our animal facility. We
found that also in mice fed 60% HFD for 24 weeks the GVB
was disrupted, as assessed by PV-1 staining both in the ileum
and colon (Fig. 2A,B). This correlated with an increase of LPS
translocation in the bloodstream (Fig. 2C). The induction of
NASH was confirmed by the presence of lipid accumulation in
the liver (Oil Red O staining, Fig. 2D), fibrosis (Sirius red staining
for collagen fibers, Fig. 2D) and increased serum aminotrans-
ferases (ALT, Fig. 2E). The mice also displayed insulin resistance,
as assessed by an altered response to glucose and insulin toler-
ance tests (Fig. 2F). Clear signs of inflammation in the liver were
observed, with an increase of inflammatory cytokines and
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1222 Journal of Hepatology 20chemokines (Ifn-c, Il33 and Ccl2) (Fig. 2G) and of immune cells
(CD45+ cells), in particular CD4+ and CD8+ T cells, monocytes
and macrophages (Fig. 2H).
These results indicate that, early after HFD feeding, IEB dis-
ruption leads to bacterial translocation, which is followed by
GVB disruption. GVB disruption is maintained throughout the
development of NASH and inflammation-driven insulin resis-
tance and obesity.
Increased vascular permeability allows bacterial
translocation to the liver
Having observed bacteria translocation across the epithelium,
we hypothesized that if the GVB was effectively disrupted, as
shown by increased PV1 expression, we should also detect
bacteria in the liver. To detect the presence and the location
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OF HEPATOLOGYof bacteria, we performed FISH analysis with probes to detect
eubacteria 16S rRNA region and immunostaining for CD45 to
detect immune cells. We found that livers of control diet-fed
mice were harboring few bacteria, which were mostly within
CD45+ immune cells, although it is unclear if these were resi-
dent liver bacteria or were shuttled from elsewhere (Fig. 3A,
B). By contrast, in the livers of HFD-fed mice, bacteria were
found in the parenchyma, outside immune cells (Fig. 3A,B), sug-
gesting their free migration to the liver. In agreement with the
increased bacterial translocation, LPS levels in the serum of
mice fed with HFD were consistently higher than in mice fed
with control diet (Fig. 3C).
To functionally assess whether the GVB was effectively
disrupted, we carried out fluorescent endomicroscopy using
the Cellvizio technology.22 Mice were fed with HFD or control
diet for 1 week before a high molecular weight FITC-dextran
fluorescent probe (500 kDa), resembling the size of a bacterium,
was administered intravenously. The capacity of the dye to
extravasate into the lamina propria of the ileum was evaluated
by fluorescent intravital endomicroscopy. Using this approach,
we address only GVB permeability, as the dye would migrate
from the blood lumen into the lamina propria. Confirming
that increased permeability leads to bacterial translocation
(Fig. 3A,B), we found that in HFD-fed mice, but not control
diet-fed mice, the intestinal blood vessels had become
permeable to the dye (Fig. 3D–F). Interestingly, despite
increased weight and adipose tissue size, the observed GVB
and IEB disruptions preceded any sign of liver steatosis,
adipocyte enlargement, or pancreatic damage, as shown by
ORO staining or histology (Fig. S3).
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Journal of Hepatology 20Similar results were obtained following 6 weeks of HFD feed-
ing in female C57BL/6 mice, which display delayed disease
development and a broader window of pre-diabetic state23
(Fig. S4A). Also in this case, mice increased their body mass
and visceral adipose tissue (Fig. S4B) and, in the absence of liver
steatosis or insulin resistance (Fig. S4C,D), they displayed
increased PV1 and reduced ZO-1 expression on intestinal blood
endothelial cells (Fig. S4E). Taken together, the increased
endothelial permeability and bacterial translocation during
HFD indicate that GVB disruption is an early event in NASH
development, preceding liver steatosis.
A dysbiotic microbiota can affect GVB integrity
It is known that HFD induces a change in microbiota
composition in mice.24 Thus, having observed that IEB and
GVB disruption are early events prompted by HFD, we assessed
if the diet-induced microbiota changes were responsible for
GVB disruption, by carrying out fecal microbiota transplantation
(FMT). The possible involvement of the microbiota in
controlling the GVB is suggested by our observation that adult
germ-free mice show increased expression of PV1 compared
to SPF mice (data not shown). However, microbiota reconstitu-
tion of germ-free mice does not lead to PV1 normalization, sug-
gesting an impairment in GVB which cannot be corrected by the
microbiota, at least in adult mice (data not shown). Further-
more, GF mice are resistant to HFD-induced NASH, confirming
our hypothesis that bacterial translocation across the intestine
is responsible for NASH development.25 For these reasons we
performed FMT in SPF mice. Donor mice were fed HFD or con-
trol diet, and after 1 week, their microbiota from the feces and
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Research Article Genetic and Metabolic Diseasesassociated mucus (see Methods) were collected and transferred
into recipient mice (Fig. 3G). Recipient mice were maintained on
a standard chow diet, and a week later analyzed for weight gain
and sacrificed to collect their organs. As shown in Fig. 3H, mice
receiving FMT from HFD-fed mice displayed increased epididy-
mal adipose tissue (EAT) even if they were fed a standard diet,
compared to recipients receiving FMT from mice under control
diet. In addition, the GVB of mice treated with FMT from HFD-
fed mice displayed increased PV1 expression (Fig. 3I,J).
Together, these results indicate that HFD modifies the micro-
biota, inducing dysbiosis that affects the GVB and correlates
with increased intestinal blood vessel permeability.
GVB disruption is a prerequisite for NASH induction
Having observed a disruption of the GVB during HFD, we
assessed its role in NASH induction. We have previously shown
that interference with the WNT/b-catenin signaling pathway in
endothelial cells is a mechanism adopted by Salmonella typhi-
murium to induce GVB disruption.13 We thus forced b-catenin
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choline-deficient diet; MFI, mean fluorescence intensity; NASH, non-alcoholic1224 Journal of Hepatology 20activation in mice only in endothelial cells, using VE-cadherin
Cre (Cdh5(PAC)-creERT2) mice crossed to b-catlox(ex3)/lox(ex3),
which contain 2 flox sequences flanking exon 3 of the
b-catenin gene. Upon tamoxifen administration, in Cre+ mice,
exon 3 of b-catenin is deleted, leading to a non-degradable form
of b-catenin and a gain-of-function (GOF) phenotype.13 When
b-catenin is constitutively activated, the GVB cannot be
disrupted.13 We used, as controls, either exon3 floxed mice
(b-catlox(ex3)/lox(ex3)), or Cre- littermate mice, born from the same
mothers (sharing the same microbiota), with similar results.
Cre+ and Cre mice were fed control diet or HFD for 1 week,
as above, and PV1 accessibility was assessed. As shown in
Fig. 4A,B, HFD was not capable of inducing PV1 upregulation
in b-catenin GOF mice. As expected, as the GOF is only occurring
in endothelial cells, leaving epithelial cells unaffected, bacteria
could still translocate into the ileum and cecum after HFD
(Fig. 4C and data not shown).
We next analyzed bacterial translocation to the liver, and
found that Cre+ b-catenin GOF mice, when fed HFD, resembled
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tight junction proteins, resulting in GVB protection and
endothelial cell sealing.
tested PV1 expression on colonic biopsies obtained during colo-
noscopy of 9 patients with NASH (see demographic characteris-
get for pharmacologic intervention. We found that the FXR ago-
nist OCA could activate the WNT/b-catenin signaling pathway
While MCDD is not a good model of obesity-induced NASH, as it
JOURNAL 
OF HEPATOLOGYcontrol diet-fed mice (Fig. 4D,E). In HFD-fed Cre mice, we could
find free bacteria, not internalized by CD45+ immune cells,
whereas most of the bacteria detected in the Cre+ mice were
within immune cells. This suggests that, in the presence of an
intact GVB, translocation of free bacteria into the liver is
impeded. When mice were fed HFD for a longer period, to
induce liver steatosis, we observed that Cre+ GOF mice dis-
played no adipocyte enlargement (Fig. 4F,G) and were com-
pletely protected from NAFLD, as shown by histology and the
lack of lipid accumulation in the liver (Fig. 4F). In Cre+ GOF mice
we also observed an improvement in blood glucose levels
induced by HFD (Fig. S5A).
Interestingly, HFD feeding for 10 days led to leukocyte
recruitment, including CD8+ T cells and inflammatory mono-
cytes, in the adipose tissue of Cre but not Cre+ GOF mice
(Fig. S5B,C). Together, these results indicate that impairment
of IEB alone is not sufficient to induce NASH and that GVB dis-
ruption is also required.
The FXR agonist obeticholic acid as a pharmacologic
treatment to protect GVB integrity
As mentioned above, OCA has been shown to ameliorate NASH
in animal models26 and in patients.19,20 OCA also protects
against inflammation-induced epithelial permeability via FXR-
dependent mechanisms17,18 and reduces bacterial translocation
to mesenteric lymph nodes in cholestatic18 and in cirrhotic
rats.27 We thus evaluated whether OCA could affect HFD-
induced intestinal permeability by targeting the GVB. We fed
mice with HFD or control diet and orally administered OCA
(30 mg/kg for 1 week). Interestingly, we observed that OCA
inhibits the upregulation of PV1 (Fig. 5A–C) and increases ZO-
1 expression (Fig. S6), suggesting a greater GVB tightness. We
then asked if controlling PV1 expression leads to GVB protec-
tion. Mice were fed with HFD or control diet for 1 week, with
or without OCA, and then administered intravenously with the
high molecular weight (500 kDa) fluorescent probe FITC-
dextran. We found that OCA administration reduced extravasa-
tion of the dye, suggesting that OCA functionally protects the
GVB from disruption (Fig. 5D–F).
In addition to the Western diet-like HFD model, inducing a
metabolic disorder similar to mild human NASH, we also tested
the MCDDmodel, which recapitulates more severe NASH patho-
logic features.21 We first evaluated whether MCDD could induce
perturbations in the GVB. Mice were fed an MCDD or chow diet
for 1 week, and the expression of PV1 was evaluated in the
ileum. As shown in Fig. S7, MCDD induced a marked upregula-
tion of PV1 expression, which was corrected by OCA administra-
tion. These results indicate that MCDD also induces GVB
damage and that OCA is also protective in this model.
To evaluate the therapeutic efficacy of OCA in ameliorating
NASH, we administered the drug to mice fed with MCDD for
2 weeks, after the onset of liver damage assessed by increased
ALT concentrations in the serum and lipid accumulation in the
liver. OCA was then administered daily via oral gavage for the
following 2 weeks in mice still fed MCDD (Fig. 6A). We observed
that the upregulated PV1 expression induced by MCDD was
restored by OCA in the ileum and colon, indicating its ability
to seal a damaged GVB and to prevent further MCDD-induced
damage (Fig. 6B,C). Moreover, 2 weeks of OCA treatment cured
the liver damage, reducing ALT levels and lipid accumulation
in the liver (Fig. 6D,E). These data suggest a role for OCA, likely
via FXR activation, in controlling GVB integrity either indirectlyJournal of Hepatology 20via epithelial cells or directly through an effect on endothelial
cells. Indeed, FXR is expressed in endothelial cells,28 where it
regulates inflammation,28 vascular tension,29 and improves
erectile function.30
As GVB integrity is controlled by the WNT/b-catenin signal-
ing pathway, we assessed whether OCA could activate this path-
way. Primary endothelial cells were exposed to OCA and the
expression of b-catenin downstream target genes was evalu-
ated. As shown in Fig. S8, not only Lef1 and Ccdn1 b-catenin tar-
get genes were upregulated by OCA but also genes coding for
tight junction proteins Cldn5 and Zo-1. Collectively, these results
indicate that OCA can directly target endothelial cells by activat-
ing the WNT/b-catenin signaling pathway and upregulatingPatients with NASH display GVB impairment
Having shown that GVB impairment is a prerequisite for NASH
development, we analyzed whether we could also detect upreg-
ulation of PV1 in the intestines of patients with NASH. Wetics of NASH patients). As a control, we analyzed the healthy
portion of colon from tumor bearing patients. As shown in
Fig. 6F,G, patients with NASH displayed upregulation of PV1 in
gut endothelial vessels, suggesting that the GVB is also compro-
mised in the pathogenesis of NASH in humans.Discussion
A role for the intestinal barrier in the development of liver dis-
orders has been postulated, but several questions are still
open.14 It is not clear, for instance, if increased intestinal perme-
ability is a cause or a consequence of liver disease, particularly
in NASH.9 Here, we have clearly connected the microbiota with
increased epithelial and gut vascular permeability as well as
with NASH development. We have shown that disruption of
the GVB is an early event in NASH pathogenesis and is a conse-
quence of diet-induced dysbiosis. Damage of the GVB is sus-
tained as it is still observed in an inflammatory model of
NASH (HFD 60%). We have also shown that GVB disruption is
required for NASH development and that the GVB is a new tar-and thus seal the GVB. Consistent with this observation, OCA
administration during HFD feeding inhibited the upregulation
of PV1 in the GVB and the subsequent increased permeability,
and was also able to restore PV1 expression in the MCDDmodel.is not associated with insulin resistance, a role of OCA in protec-
tion in an HFD-induced NASH model has recently been demon-
strated in a therapeutic setting, indicating that FXR-engagement
may be protective in several models where the GVB is dis-
rupted.31 OCA could act directly on endothelial cells or indi-
rectly via epithelial cells to control PV1 expression and GVB
function. However, the finding that mice deficient for FXR in
the intestinal epithelium are not susceptible to NASH or liver
steatosis,32 suggests a role for endothelial FXR in controlling
GVB permeability and NASH development. Consistent with this
observation, and with a sustained disruption of the GVB, we also
found that patients with NASH display a disrupted GVB, as
demonstrated by increased PV1 expression on gut vessels.19 vol. 71 j 1216–1228 1225
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including NASH,33,34 and a metagenomic signature with
increased Proteobacteria and reduced Firmicutes is predictive
of liver fibrosis in patients with NASH.34 We show that micro-
biota from mice fed HFD for just 1 week was sufficient to dis-
rupt the GVB and increase EAT when transplanted into
standard diet-fed mice. Consistent with a role of the microbiota
in NASH development, FMT from patients with NASH worsens
diet-induced NASH in mouse models.35 Similarly, the micro-
biota from mice with inflammasome deficiency exacerbate hep-
atic steatosis and inflammation through translocation of TLR4
and TLR9 agonists into the portal circulation in another model
of NASH.36 This is in line with our findings that HFD drives dys-
biosis, leading to the impairment of the GVB, and subsequently
the release of bacteria into the systemic circulation. As liver bac-
teria were not associated with CD45+ immune cells, we propose
that they migrate freely into the liver after crossing first the IEB
and entering the portal circulation through the damaged GVB.
We have shown that the capacity of bacteria to cross the GVB
is an active mechanism which, in the case of Salmonella typhi-
murium, is dependent on the Salmonella pathogenicity island
II.13 Thus, it is likely that HFD-induced dysbiosis results in bac-
teria being able to cross a compromised GVB. We cannot
exclude that there may be cooperation between microbes and
that some may be capable of crossing the IEB, while others
the GVB. Bacterial translocation during HFD may induce sus-
tained inflammation, that together with the high content of
lipids in the diet, may drive the metabolic disorder, leading to
insulin resistance which is not observed in other NASH models.
Alternatively, HFD has been shown to affect the composition of
bile acids,37 which may on one side change the microbiota com-
position,38 and on the other affect the activation of FXR, with
clear effects on barrier properties. It is likely that the modified
microbiota may in turn change the bile acid composition, lead-
ing to an amplification of the effect.
In conclusion, these results indicate that increased intestinal
permeability due to deranged GVB is responsible for the translo-
cation of whole bacteria or bacterial products through the portal
circulation into the liver, and eventually into the systemic circu-
lation. By only protecting the GVB, through the activation of the
WNT/b-catenin signaling pathway in endothelial cells, we can
prevent NASH and the associated metabolic syndrome, pointing
to the GVB as a new therapeutic target. However, as we could
not control the activation of the WNT/b-catenin signaling path-
way only in intestinal endothelial cells, we cannot exclude a
concomitant effect of activation of this pathway in liver
endothelium. This may contribute to control direct lipid access
to the liver from the systemic circulation. This is unlikely as
lipid absorption occurs mainly through chylomicrons, large
lipoprotein particles unable to enter capillaries, but picked up
by the lacteals, lymphatic capillaries that poke up into the cen-
ter of each villus.39
We have shown that targeting the FXR with OCA can lead to
activation of the WNT/b-catenin signaling pathway in endothe-
lial cells and sealing of the GVB, even in a therapeutic setting,
thus inhibiting further translocation of potentially harmful bac-
teria and their determinants, with clear effects on NASH control.
This may contribute to explain the beneficial effects of OCA in
patients with NASH.20
The beneficial effects of preserving IEB and GVB integrity
may extend beyond liver disorders, as intestinal alterations
and gut mucosal inflammation have also been observed in other
1226 Journal of Hepatology 20systemic diseases.40–44 A high percentage of patients with
autism spectrum disorders,40–44 for instance, and their first-
degree relatives are characterized by increased intestinal per-
meability compared to healthy children.45 Similarly, evidence
suggests that increased gut permeability may precede or occur
concomitantly with type I diabetes, as early evidence of the dis-
ease occurs in association with an enteropathy.46,47 The higher
permeability of the gut barrier may allow the uptake of dietary
antigens, favoring autoimmunity.48 Hence, understanding the
role of the IEB and, in particular, of the GVB in other systemic
disorders may lead to clinical benefit in the entire gut-liver-
brain axis and may provide new opportunities for therapeutic
intervention.
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